|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCDHGC3 |
Gene summary for PCDHGC3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCDHGC3 | Gene ID | 5098 |
| Gene name | protocadherin gamma subfamily C, 3 | |
| Gene Alias | PC43 | |
| Cytomap | 5q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | Q9BR81 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5098 | PCDHGC3 | LZE24T | Human | Esophagus | ESCC | 1.18e-03 | 1.17e-01 | 0.0596 |
| 5098 | PCDHGC3 | P2T-E | Human | Esophagus | ESCC | 4.02e-11 | 1.67e-01 | 0.1177 |
| 5098 | PCDHGC3 | P5T-E | Human | Esophagus | ESCC | 1.15e-05 | 9.93e-02 | 0.1327 |
| 5098 | PCDHGC3 | P8T-E | Human | Esophagus | ESCC | 1.19e-03 | 8.12e-02 | 0.0889 |
| 5098 | PCDHGC3 | P10T-E | Human | Esophagus | ESCC | 1.63e-12 | 1.40e-01 | 0.116 |
| 5098 | PCDHGC3 | P11T-E | Human | Esophagus | ESCC | 3.00e-06 | 2.90e-01 | 0.1426 |
| 5098 | PCDHGC3 | P12T-E | Human | Esophagus | ESCC | 3.72e-12 | 2.11e-01 | 0.1122 |
| 5098 | PCDHGC3 | P16T-E | Human | Esophagus | ESCC | 2.67e-13 | 2.36e-01 | 0.1153 |
| 5098 | PCDHGC3 | P17T-E | Human | Esophagus | ESCC | 7.57e-03 | 2.49e-01 | 0.1278 |
| 5098 | PCDHGC3 | P20T-E | Human | Esophagus | ESCC | 7.60e-12 | 3.09e-01 | 0.1124 |
| 5098 | PCDHGC3 | P21T-E | Human | Esophagus | ESCC | 3.95e-09 | 1.42e-01 | 0.1617 |
| 5098 | PCDHGC3 | P22T-E | Human | Esophagus | ESCC | 2.90e-07 | 1.24e-01 | 0.1236 |
| 5098 | PCDHGC3 | P23T-E | Human | Esophagus | ESCC | 1.18e-10 | 2.52e-01 | 0.108 |
| 5098 | PCDHGC3 | P24T-E | Human | Esophagus | ESCC | 6.22e-03 | 1.35e-01 | 0.1287 |
| 5098 | PCDHGC3 | P26T-E | Human | Esophagus | ESCC | 1.08e-11 | 2.48e-01 | 0.1276 |
| 5098 | PCDHGC3 | P28T-E | Human | Esophagus | ESCC | 1.06e-05 | 6.73e-02 | 0.1149 |
| 5098 | PCDHGC3 | P30T-E | Human | Esophagus | ESCC | 9.84e-05 | 2.11e-01 | 0.137 |
| 5098 | PCDHGC3 | P31T-E | Human | Esophagus | ESCC | 1.51e-10 | 1.97e-01 | 0.1251 |
| 5098 | PCDHGC3 | P32T-E | Human | Esophagus | ESCC | 2.29e-15 | 3.74e-01 | 0.1666 |
| 5098 | PCDHGC3 | P36T-E | Human | Esophagus | ESCC | 1.34e-12 | 4.60e-01 | 0.1187 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCDHGC3 | SNV | Missense_Mutation | novel | c.1067N>T | p.Ser356Phe | p.S356F | Q9UN70 | protein_coding | deleterious(0.04) | benign(0.028) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| PCDHGC3 | SNV | Missense_Mutation | rs748024579 | c.2399N>G | p.Val800Gly | p.V800G | Q9UN70 | protein_coding | tolerated(0.39) | possibly_damaging(0.755) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| PCDHGC3 | SNV | Missense_Mutation | rs748024579 | c.2399N>G | p.Val800Gly | p.V800G | Q9UN70 | protein_coding | tolerated(0.39) | possibly_damaging(0.755) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| PCDHGC3 | SNV | Missense_Mutation | rs370299433 | c.244N>A | p.Glu82Lys | p.E82K | Q9UN70 | protein_coding | tolerated(0.27) | benign(0.007) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| PCDHGC3 | SNV | Missense_Mutation | c.547N>T | p.Arg183Cys | p.R183C | Q9UN70 | protein_coding | deleterious(0.02) | benign(0.001) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| PCDHGC3 | SNV | Missense_Mutation | novel | c.817G>A | p.Glu273Lys | p.E273K | Q9UN70 | protein_coding | deleterious(0.03) | possibly_damaging(0.704) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| PCDHGC3 | SNV | Missense_Mutation | novel | c.2325A>C | p.Lys775Asn | p.K775N | Q9UN70 | protein_coding | tolerated(0.18) | possibly_damaging(0.723) | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| PCDHGC3 | SNV | Missense_Mutation | c.432N>G | p.Ile144Met | p.I144M | Q9UN70 | protein_coding | tolerated(0.05) | probably_damaging(0.981) | TCGA-BH-A0DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PCDHGC3 | SNV | Missense_Mutation | rs748024579 | c.2399T>G | p.Val800Gly | p.V800G | Q9UN70 | protein_coding | tolerated(0.39) | possibly_damaging(0.755) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCDHGC3 | SNV | Missense_Mutation | rs748024579 | c.2399N>G | p.Val800Gly | p.V800G | Q9UN70 | protein_coding | tolerated(0.39) | possibly_damaging(0.755) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |